Until now, state-funded ARV treatment has comprised three different pills taken at different times during the day. The new FDA combines the three key agents from these pills in a single pill that only needs to be taken once a day.
Although welcoming the FDAs as easier and more convenient for patients, activists and health professionals alike have warned that a stockout of the drug could have a catastrophic effect on the country’s public HIV/AIDS treatment programme - the largest of its kind in the world.
The Anova Health Institute welcomes the move by the Medicines Control Council (MCC) after they officially registered the use of a combination of two antiretroviral drugs as a form of pre-exposure prophylaxis (PrEP) medication. This pill, taken daily by the HIV negative individuals, can drastically reduce HIV infection.
Prof James McIntyre, CEO of Anova, says: “This is a major advance in HIV prevention in South Africa, with the potential to save many lives. The evidence is clear, PrEP works if you take it. Not everyone will need or want PrEP, or require it forever, but it can provide almost complete protection against infection if taken consistently. Our challenge is to educate users and move rapidly to ensure access for those who need it.”
Dr Kevin Rebe, Specialist Medical Consultant at Anova’s Health4Men Initiative, says: “The approval of PrEP is a major step forward in the fight against HIV. It is extremely effective and safe to use. It can reduce the risk of HIV by more than 90% in HIV negative people who use it correctly. This announcement will greatly facilitate the work that Anova conducts in HIV prevention. Our challenge now is to create demand for PrEP and to work towards removing barriers to access.”
Anova, in collaboration with the Desmond Tutu HIV Research Unit, already has a PrEP demonstration project underway within state sector clinics. Anova is working to develop tools that will allow PrEP to be nurse-driven and scaled up by the Department of Health.